BioArctic AB/Skr BIOA B
1D1W1MYTD1Y5YMAX
Capital at risk
About BioArctic AB
BioArctic AB is a Swedish biopharmaceutical company focusing on developing treatments for central nervous system disorders. The company is notably engaged in the research and development of therapies for neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. Founded in 2003, BioArctic collaborates with academic institutions and global pharmaceutical companies to advance its innovative approaches. The company is headquartered in Stockholm, Sweden, and leverages its strategic partnerships and scientific expertise to address unmet medical needs in its chosen field. BioArctic's competitive strengths include its proprietary technology platforms and strong intellectual property portfolio.
- Ticker
- Skr BIOA B
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 150
- Headquarters
- Stockholm, Sweden
- Website
- www.bioarctic.se
BioArctic AB Metrics
BasicAdvanced
kr 28B
268.67
kr 1.18
-0.68
kr 2.00
0.63%
Price and volume
Market cap
kr 28B
Beta
-0.68
52-week high
kr 364.40
52-week low
kr 257.00
Average daily volume
168K
Dividend rate
kr 2.00
Financial strength
Current ratio
3.992
Quick ratio
2.967
Long term debt to equity
0.036
Total debt to equity
0.045
Profitability
Gross margin (TTM)
93.17%
Net profit margin (TTM)
10.53%
Operating margin (TTM)
19.62%
Effective tax rate (TTM)
57.56%
Revenue per employee (TTM)
kr 6,680,000
Management effectiveness
Return on assets (TTM)
4.78%
Return on equity (TTM)
5.21%
Valuation
Price to earnings (TTM)
268.671
Price to revenue (TTM)
28.136
Price to book
13.99
Price to tangible book (TTM)
13.99
Price to free cash flow (TTM)
120.675
Free cash flow yield (TTM)
0.83%
Free cash flow per share (TTM)
2.637
Dividend yield (TTM)
0.63%
Forward dividend yield
0.63%
Growth
Revenue change (TTM)
-46.09%
Earnings per share change (TTM)
-90.14%
3-year revenue growth (CAGR)
17.57%
3-year earnings per share growth (CAGR)
-26.96%
Bulls say / Bears say
Sales of Leqembi® reached JPY 29.3 billion in Q2 2026, up sequentially from JPY 26.2 billion in Q1, driving BioArctic’s royalty revenues up approximately 43% year‐over‐year and underpinning its near‐term financial outlook (BioArctic)
On July 13, 2026, the FDA approved Leqembi Iqlik® subcutaneous injection as an at‐home initiation option for early Alzheimer’s disease, enhancing patient convenience and likely expanding Leqembi’s addressable market (BioArctic)
BioArctic secured USD 30 million upfront and up to USD 770 million in potential milestones through its June 22, 2026 collaboration with Eli Lilly to combine Lilly’s compound with its BrainTransporter™ technology, diversifying its pipeline and de‐risking future revenue streams (BioArctic)
BioArctic’s pipeline beyond Leqembi remains largely preclinical or in early‐phase stages, delaying potential revenue streams and increasing clinical development risk (BioArctic)
The company’s revenue model is heavily dependent on milestone payments and royalties from Eisai and Biogen, resulting in lumpy cash flows tied to partners’ commercial execution and strategic decisions (BioArctic)
Biogen’s tau‐targeting Alzheimer’s candidate showed promising mid‐stage signs of benefit, representing emerging competition that could challenge amyloid‐targeting therapies like Leqembi (Bloomberg)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
Upcoming events
No upcoming events
Funds containing BioArctic AB
AllUSDEURGBP
Fund name | Fund size | Skr BIOA B weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.15% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.15% |
iShares Healthcare Innovation£DRDR | £1B | 0.15% |
iShares Ageing Population€AGED | €822M | 0.12% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.